| Q64072637 | A Lactic Acid Bacteria (LAB)-Based Vaccine Candidate for Human Norovirus |
| Q40148601 | A Luciferase Immunoprecipitation System (LIPS) assay for profiling human norovirus antibodies. |
| Q37074502 | A mouse model for human norovirus |
| Q38081825 | A review of known and hypothetical transmission routes for noroviruses |
| Q90179121 | A robust human norovirus replication model in zebrafish larvae |
| Q35568903 | A working model of how noroviruses infect the intestine |
| Q27016152 | Advances in norovirus biology |
| Q92305462 | Animals as Reservoir for Human Norovirus |
| Q37101808 | Anti-norovirus therapeutics: a patent review (2010-2015). |
| Q30249527 | Antiviral targets of human noroviruses |
| Q50041698 | Attempts to grow human noroviruses, a sapovirus, and a bovine norovirus in vitro. |
| Q35652068 | Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax |
| Q38833628 | Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases |
| Q35212408 | Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial |
| Q40264649 | Carbon Dots' Antiviral Functions Against Noroviruses |
| Q39038924 | Characterization of the chemokine response of RAW264.7 cells to infection by murine norovirus. |
| Q35192903 | Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period |
| Q36157186 | Complicated norovirus infection and assessment of severity by a modified Vesikari disease score system in hospitalized children |
| Q35826200 | Contribution of intra- and interhost dynamics to norovirus evolution |
| Q36414470 | Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication |
| Q34778430 | Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis |
| Q50428969 | Editorial Commentary: Noroviruses and B Cells |
| Q30425145 | Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes |
| Q90249039 | Emergence of norovirus strains: A tale of two genes |
| Q34446799 | Enteric bacteria promote human and mouse norovirus infection of B cells |
| Q36835594 | Enterobacter cloacae inhibits human norovirus infectivity in gnotobiotic pigs. |
| Q38134997 | Epidemiology, prevention, and control of the number one foodborne illness: human norovirus |
| Q27302049 | Experimental inoculation of juvenile rhesus macaques with primate enteric caliciviruses |
| Q47589746 | Experimental miniature piglet model for the infection of human norovirus GII. |
| Q28590071 | Functional receptor molecules CD300lf and CD300ld within the CD300 family enable murine noroviruses to infect cells |
| Q35665784 | Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity |
| Q64085317 | Genomics Analyses of GIV and GVI Noroviruses Reveal the Distinct Clustering of Human and Animal Viruses |
| Q64251825 | Human Norovirus: Experimental Models of Infection |
| Q30401642 | Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades |
| Q36399672 | Human norovirus culture in B cells |
| Q37576247 | Human norovirus detection and production, quantification, and storage of virus-like particles |
| Q96126983 | Human norovirus targets enteroendocrine epithelial cells in the small intestine |
| Q30250236 | Human norovirus transmission and evolution in a changing world |
| Q34785721 | Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid. |
| Q35638367 | Identification of a novel cellular target and a co-factor for norovirus infection - B cells & commensal bacteria |
| Q34987998 | Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains |
| Q24810360 | Immunogenetic mechanisms driving norovirus GII.4 antigenic variation |
| Q35983587 | Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations |
| Q38374766 | Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination |
| Q92854248 | In Vitro Replication of Human Norovirus |
| Q42088280 | In vitro whole-virus binding of a norovirus genogroup II genotype 4 strain to cells of the lamina propria and Brunner's glands in the human duodenum. |
| Q36841045 | Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency |
| Q38831050 | Infectivity of a recombinant murine norovirus (RecMNV) in Balb/cByJ mice |
| Q47558073 | Interactions between Enteric Bacteria and Eukaryotic Viruses Impact the Outcome of Infection |
| Q33703664 | Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder |
| Q36826001 | Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells |
| Q39925244 | Mapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell |
| Q37109677 | Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. |
| Q35760516 | Molecular chaperone Hsp90 is a therapeutic target for noroviruses |
| Q40886765 | Molecular characterization and pathogenicity of a genogroup GVI feline norovirus |
| Q30409563 | Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. |
| Q36155501 | Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens |
| Q57297793 | Non-Human Primate Models of Enteric Viral Infections |
| Q26864280 | Norovirus |
| Q36907013 | Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB. |
| Q41927114 | Norovirus Cell Tropism Is Determined by Combinatorial Action of a Viral Non-structural Protein and Host Cytokine. |
| Q37664430 | Norovirus GII.17 Natural Infections in Rhesus Monkeys, China |
| Q40083265 | Norovirus Loads in Stool Specimens of Cancer Patients with Norovirus Gastroenteritis. |
| Q34702360 | Norovirus P particle efficiently elicits innate, humoral and cellular immunity |
| Q40743794 | Norovirus antagonism of B-cell antigen presentation results in impaired control of acute infection |
| Q90748454 | Norovirus antivirals: Where are we now? |
| Q31121082 | Norovirus binding to intestinal epithelial cells is independent of histo-blood group antigens |
| Q27694610 | Norovirus gastroenteritis in immunocompromised patients |
| Q42951740 | Norovirus gastroenteritis in immunocompromised patients |
| Q28083087 | Norovirus immunology: Of mice and mechanisms |
| Q39167685 | Norovirus infection in primary immune deficiency |
| Q36275589 | Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives |
| Q37135476 | Norovirus vaccines: Correlates of protection, challenges and limitations |
| Q38081967 | Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis |
| Q38217316 | Norovirus: targets and tools in antiviral drug discovery |
| Q38130186 | Noroviruses and histo-blood groups: the impact of common host genetic polymorphisms on virus transmission and evolution. |
| Q38322750 | Noroviruses: epidemiology, immunity and prospects for prevention |
| Q57055717 | Osmolytes in vaccine production, flocculation and storage: a critical review |
| Q34059136 | Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope |
| Q36911792 | Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses |
| Q36642590 | Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation |
| Q34058600 | Prevalence of recovirus-neutralizing antibodies in human serum samples |
| Q38557262 | Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations |
| Q38160537 | Progress towards the prevention and treatment of norovirus infections |
| Q30155275 | RETRACTED: Norovirus RNA synthesis is modulated by an interaction between the viral RNA-dependent RNA polymerase and the major capsid protein, VP1. |
| Q37517465 | Recent Advances in the Discovery of Norovirus Therapeutics |
| Q38816488 | Recent advances in understanding norovirus pathogenesis |
| Q38761262 | Recent advances in understanding noroviruses |
| Q33761808 | Relationship between genotypes and serotypes of genogroup 1 recoviruses: a model for human norovirus antigenic diversity |
| Q34538562 | Replication of human noroviruses in stem cell-derived human enteroids |
| Q92877840 | Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination |
| Q34426666 | Seroprevalence of norovirus genogroup IV antibodies among humans, Italy, 2010-2011. |
| Q27682135 | Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds |
| Q37323139 | Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody |
| Q34883353 | Subgenomic promoter recognition by the norovirus RNA-dependent RNA polymerases |
| Q63880718 | Targeting macrophage- and intestinal epithelial cell-specific microRNAs against norovirus restricts replication in vivo. |
| Q64947514 | The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics. |
| Q59360163 | The Dual Tropism of Noroviruses |
| Q34388075 | The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. |
| Q35916845 | The influence of commensal bacteria on infection with enteric viruses |
| Q48355926 | The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue |
| Q38259875 | The molecular pathology of noroviruses |
| Q33678125 | The state of norovirus vaccines |
| Q36691408 | Treatment of norovirus infections: moving antivirals from the bench to the bedside |
| Q33578075 | Vaccine against norovirus |
| Q38766728 | Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses |